Scholarlink

Background <p>Studies have discussed the efficacy of bariatric surgery (BS) in remission of individual components of metabolic syndrome (MS). We aimed to analyse the prevalence of MS following BS.</p> Methods <p>On October 5, 2023, we conducted a literature search on PubMed, Scopus, Web of Science, and Cochrane. RevManv5.4 was used for the analysis.</p> Results <p>MS patients who underwent BS had lower odds of MS within the first year post-BS (OR 0.14, 95%CI 0.12–0.17); patients who had a preoperative BMI &lt; 50 showed a higher reduction in MS post-BS compared with patients who suffered from super obesity (OR 0.12 versus OR 0.17). Older patients (age &gt; 42) had lower odds of MS post-BS compared with younger patients (OR 0.05 versus OR 0.17). There was not a difference in MS prevalence between 1 and 2&#xa0;years postoperatively (OR 1.07, 95%CI 0.72–1.58). Asians reported the highest reduction in MS post-BS (OR 0.08). MS patients who received medical treatment had three times the odds of having MS compared with patients who underwent BS. Patients who had BS reported a decline in their anti-hypertensives and oral anti-diabetic drugs (OR 0.26, 95%CI 0.15–0.46, OR 0.11, 95%CI 0.07–0.16, respectively). There was not a significant difference in MS prevalence between patients who underwent RYGB and those who had SG (OR 2.16, 95%CI 0.74–6.26).</p> Conclusions <p>BS is superior to medical treatment in the remission of MS. Age, preoperative BMI, and country of origin affect the rates of MS remission. BS results in a sustainable resolution of MS across 1, 2, and 5&#xa0;years post-surgery. A tailored approach is warranted to achieve the best outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bariatric Surgery and Remission of Metabolic Syndrome: A Meta-analysis of Randomised Controlled Trials and Prospective Studies

  • 期刊论文

  • 发表日期：

    2025年2月25日

查看全文
  • Yomna E. Dean,
  • Mohamed I. Mohamed,
  • Abdulrahman Shokri,
  • Moussa Nassar,
  • Abu Omayer,
  • Maryam Shahid,
  • Arsalan Sharif,
  • Zakaria Soliman,
  • Yasser Almadani,
  • Abdelrahman Yakout,
  • Asim Eren Guvem,
  • Urvij Jaiswal,
  • Adham Hamza,
  • Mohamed Zein,
  • Mohamed M. Elnemr,
  • Shabab Shahabi,
  • Mohammad Kermansaravi,
  • Wah Yang,
  • Tamer N. Abdelbaki

摘要

Background

Studies have discussed the efficacy of bariatric surgery (BS) in remission of individual components of metabolic syndrome (MS). We aimed to analyse the prevalence of MS following BS.

Methods

On October 5, 2023, we conducted a literature search on PubMed, Scopus, Web of Science, and Cochrane. RevManv5.4 was used for the analysis.

Results

MS patients who underwent BS had lower odds of MS within the first year post-BS (OR 0.14, 95%CI 0.12–0.17); patients who had a preoperative BMI < 50 showed a higher reduction in MS post-BS compared with patients who suffered from super obesity (OR 0.12 versus OR 0.17). Older patients (age > 42) had lower odds of MS post-BS compared with younger patients (OR 0.05 versus OR 0.17). There was not a difference in MS prevalence between 1 and 2 years postoperatively (OR 1.07, 95%CI 0.72–1.58). Asians reported the highest reduction in MS post-BS (OR 0.08). MS patients who received medical treatment had three times the odds of having MS compared with patients who underwent BS. Patients who had BS reported a decline in their anti-hypertensives and oral anti-diabetic drugs (OR 0.26, 95%CI 0.15–0.46, OR 0.11, 95%CI 0.07–0.16, respectively). There was not a significant difference in MS prevalence between patients who underwent RYGB and those who had SG (OR 2.16, 95%CI 0.74–6.26).

Conclusions

BS is superior to medical treatment in the remission of MS. Age, preoperative BMI, and country of origin affect the rates of MS remission. BS results in a sustainable resolution of MS across 1, 2, and 5 years post-surgery. A tailored approach is warranted to achieve the best outcomes.